Rhumbline Advisers raised its holdings in shares of Zymeworks Inc. (NYSE:ZYME – Free Report) by 9.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 86,912 shares of the company’s stock after purchasing an additional 7,210 shares during the quarter. Rhumbline Advisers owned 0.12% of Zymeworks worth $740,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors have also recently made changes to their positions in the business. Rubric Capital Management LP lifted its stake in Zymeworks by 31.1% in the fourth quarter. Rubric Capital Management LP now owns 3,475,384 shares of the company’s stock worth $36,109,000 after purchasing an additional 823,990 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in Zymeworks during the 1st quarter worth $6,301,000. Jacobs Levy Equity Management Inc. lifted its holdings in shares of Zymeworks by 94.7% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 716,482 shares of the company’s stock worth $7,537,000 after buying an additional 348,441 shares during the period. Altitude Crest Partners Inc. bought a new position in shares of Zymeworks during the 1st quarter worth $1,532,000. Finally, O Shaughnessy Asset Management LLC increased its stake in shares of Zymeworks by 51.5% during the first quarter. O Shaughnessy Asset Management LLC now owns 255,497 shares of the company’s stock valued at $2,688,000 after buying an additional 86,797 shares during the period. 92.89% of the stock is currently owned by institutional investors.
Zymeworks Stock Performance
Shares of NYSE ZYME opened at $12.50 on Wednesday. Zymeworks Inc. has a fifty-two week low of $6.01 and a fifty-two week high of $13.27. The company has a market cap of $883.81 million, a PE ratio of -6.98 and a beta of 1.19. The business has a 50-day simple moving average of $11.13 and a two-hundred day simple moving average of $9.89.
Analysts Set New Price Targets
Several brokerages have recently weighed in on ZYME. Stifel Nicolaus upped their price target on shares of Zymeworks from $20.00 to $21.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. HC Wainwright restated a “neutral” rating and set a $10.00 target price on shares of Zymeworks in a report on Wednesday, September 18th.
View Our Latest Stock Report on Zymeworks
Zymeworks Company Profile
Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.
Read More
- Five stocks we like better than Zymeworks
- What is a Bond Market Holiday? How to Invest and Trade
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- Energy and Oil Stocks Explained
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.